Skip to main content
perspectives
We are passionate about using our voices to advance our mission of developing life-transforming therapies for people living with serious muscle diseases.
We are passionate about using our voices to advance our mission of developing life-transforming therapies for people living with serious muscle diseases.
April 24, 2023
Cultivating A Dynamic Culture Centered Around Purpose-Driven Values
By Kate Mitchell, Vice President, Head of Human Resources
Read more
Sep 15, 2022 |

Lessons Learned on Preparing to Weather the Inevitable Challenges in Biotech

by Joshua Brumm,
President & CEO of Dyne

Read more
Oct 7, 2021 |

From the Trenches: A LifeSci VC blog

by Josh Brumm

Read more
Sep 15, 2021 | Blog

Starting a New Tradition of Support

by Molly White, Dyne’s vice president, global head of patient advocacy and engagement

Read more
Jul 8, 2021 |

Playing To Win: Building A Position Of Strength In Biotech

by Josh Brumm

Read more
April 28, 2021 | BLOG

Toward a brighter future: targeting the genetic basis of rare muscle diseases

By Romesh Subramanian, Ph.D.

Read more
April 8, 2021 | BLOG

Scaling culture with growth: how to maintain your startup’s “special sauce”

By Joshua Brumm

Read more
Jan 8, 2021 | Life Science Leader panel

Preparing to pitch in a virtual world

Featuring Joshua Brumm

Watch
Dec 16, 2020 | BLOG

Beyond the balance sheet: thinking broadly about dilution in building a transformative biotech

By Joshua Brumm

Read more
Dec 14, 2020 | BLOG

Voice of the patient – the biopharma perspective

By Molly White

Read more
Additional content
Stay connected with us on
Twitter, LinkedIn, and Facebook

Hear more from Dyne Therapeutics

We are looking forward to participating in two investor conferences in October. @ChardanCM’s 7th Annual Genetic Medicines Conference on October 3rd at 11 a.m. ET and @Jefferies Inaugural Biotech CNS/Neuro Summit, on October 12th at 9:30 a.m. ET. Read more: https://bit.ly/3LF9nmh

Hear more from our CEO, Joshua Brumm

We look forward to continuing to advance DYNE-101 to deliver a potentially transformative therapy for this underserved community.